Scientists Pinpoint Genetic Cause of Rare X-Linked Spastic Ataxia

Scientists have uncovered a key genetic cause of X-linked spastic ataxia, a rare neurodegenerative disorder. The discovery, published in Nature Communications in 2026, identifies loss-of-function mutations in the CD99L2 gene as the driver behind severe motor coordination loss and spasticity. This breakthrough could pave the way for new treatments targeting the underlying molecular mechanisms.

The study reveals that CD99L2 acts as an activator of CAPN1, a protease essential for neuronal plasticity, synaptic remodelling, and cytoskeletal stability. When CD99L2 malfunctions, CAPN1 activation fails, disrupting cellular proteostasis and triggering neurodegeneration. Patients with these mutations develop progressive spastic ataxia, marked by worsening gait instability and coordination deficits over time.

Hemizygous males carrying CD99L2 mutations experience severe, early-onset symptoms, while heterozygous females may show milder or even unnoticeable effects. This pattern aligns with X-linked inheritance, distinguishing the condition from other forms of spastic ataxia. Researchers observed that the disease follows a predictable course, with motor decline accelerating as neuronal damage accumulates.

The findings also highlight broader implications for neurodegenerative research. Since CAPN1 dysregulation is linked to multiple disorders, understanding its control by CD99L2 may inspire cross-disease therapies. Potential approaches include gene editing to restore CD99L2 function or small-molecule drugs to compensate for lost CAPN1 activation.

Ongoing work now focuses on mapping the full range of CD99L2 variants and their clinical effects. This could refine diagnostic tools and improve genetic counselling for affected families. The study underscores the value of multidisciplinary collaboration in unravelling complex inherited diseases.

The identification of CD99L2 as a critical regulator of CAPN1 provides a clear molecular target for X-linked spastic ataxia. With therapeutic strategies like gene editing and drug development now in sight, patients may soon have more effective interventions. Further research will clarify how these mutations influence disease progression and response to treatment.